Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to find the highest tolerated dose of NC-6300 that can be given to
patients with advanced solid tumors or soft tissue sarcoma. The safety and tolerability of
the drug will also be studied.